Chronic kidney diseases have one thing in common: once they start, regardless of the cause and even if it is treated, they ...

A largely overlooked structure inside our cells may play a crucial role in how the brain forms, offering new insight into ...

REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ: REVB) is a potentially high-upside clinical-stage biotechnology company focused on immune modulation and inflammatory disease ...

InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...

Scientists have taken a giant leap forward with the development of tiny microneedles designed to detect subtle but critical ...

Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin ...

For Roslyn Mannon, MD, a single patient experience inspired her path to nephrology.“The patient talked passionately about how ...

At the FSED meeting, investigators highlight SGLT2 inhibitors, finerenone, and GLP-1 or GIP agents as promising strategies to ...

Researchers investigate how birth weight determines kidney function changes following prolonged physical activity in ...

Men’s Health spoke to Thomas Kruse and Jesper Lau, two chemists responsible for creating the drug that’s revolutionized how ...

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of ...